D. Hueppe

949 total citations
47 papers, 673 citations indexed

About

D. Hueppe is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, D. Hueppe has authored 47 papers receiving a total of 673 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Hepatology, 32 papers in Epidemiology and 13 papers in Rheumatology. Recurrent topics in D. Hueppe's work include Hepatitis C virus research (47 papers), Liver Disease Diagnosis and Treatment (24 papers) and Hepatitis B Virus Studies (22 papers). D. Hueppe is often cited by papers focused on Hepatitis C virus research (47 papers), Liver Disease Diagnosis and Treatment (24 papers) and Hepatitis B Virus Studies (22 papers). D. Hueppe collaborates with scholars based in Germany, Switzerland and United States. D. Hueppe's co-authors include Stefan Mauss, U. Alshüth, Bernd Moeller, E Zehnter, F. Berger, Axel Baumgarten, Thomas Berg, Heiner Wedemeyer, Michael P. Manns and C. Sarrazin and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

D. Hueppe

41 papers receiving 654 citations

Peers

D. Hueppe
Dessislava I. Dimitrova United States
Natarajan Ravendhran United States
Fernando E. Membreno United States
Ewa Janczewska Poland
S. Pol France
Takeaki Satoh Japan
Wulf O. Boecher Germany
U. Alshüth Germany
Joann Harvey United States
Bart Fevery United States
Dessislava I. Dimitrova United States
D. Hueppe
Citations per year, relative to D. Hueppe D. Hueppe (= 1×) peers Dessislava I. Dimitrova

Countries citing papers authored by D. Hueppe

Since Specialization
Citations

This map shows the geographic impact of D. Hueppe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Hueppe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Hueppe more than expected).

Fields of papers citing papers by D. Hueppe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Hueppe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Hueppe. The network helps show where D. Hueppe may publish in the future.

Co-authorship network of co-authors of D. Hueppe

This figure shows the co-authorship network connecting the top 25 collaborators of D. Hueppe. A scholar is included among the top collaborators of D. Hueppe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Hueppe. D. Hueppe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Berg, Thomas, Peter Buggisch, D. Hueppe, et al.. (2019). Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study. SHILAP Revista de lepidopterología. 28(6). 15–26.
2.
Felden, Johann von, Johannes Vermehren, Patrick Ingiliz, et al.. (2018). High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance‐associated substitutions in hepatitis C genotype 3 infection. Alimentary Pharmacology & Therapeutics. 47(9). 1288–1295. 35 indexed citations
3.
Wedemeyer, Heiner, Jens Reimer, D. Hueppe, et al.. (2017). Long‐term outcome of chronic hepatitis C virus infection in a real‐world setting: The German LOTOS study. Liver International. 37(10). 1468–1475. 6 indexed citations
4.
Zimmermann, Tim, D. Hueppe, Stefan Mauss, et al.. (2016). Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1. Journal of Gastrointestinal and Liver Diseases. 25(1). 15–24. 4 indexed citations
5.
Ingiliz, Patrick, Stefan Christensen, Torben Kimhofer, et al.. (2016). Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV–Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01). Clinical Infectious Diseases. 63(10). 1320–1324. 44 indexed citations
6.
Ingiliz, Patrick, Stefan Christensen, Torben Kimhofer, et al.. (2016). Parameters Associated with Treatment Failure with Direct Acting Antivirals against the Hepatitis C Virus (HCV) – Results Fro the German Hepatitis C Cohort (GECCO). Journal of Hepatology. 64(2). S808–S809. 1 indexed citations
7.
Petersen, Jörg, R Heyne, Stefan Mauss, et al.. (2015). Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany. Digestive Diseases and Sciences. 61(10). 3061–3071. 34 indexed citations
8.
Buggisch, Peter, Christoph Sarrazin, Stefan Mauss, et al.. (2015). P0777 : Sofosbuvir-based treatment under real life conditions in Germany (The sofger trial). Journal of Hepatology. 62. S622–S622. 7 indexed citations
9.
Petersen, J., R Heyne, JF Schlaak, et al.. (2014). O122 EFFECTIVENESS OF TENOFOVIR DF FOR CHRONIC HEPATITIS B IN FIELD PRACTICE – 3 YEAR FINAL RESULTS FROM THE PROSPECTIVE GERMAN MULTICENTER NON-INTERVENTIONAL STUDY. Journal of Hepatology. 60(1). S51–S51. 3 indexed citations
10.
Stahmeyer, Jona T., S. Rossol, Ahmed Abdelfattah, et al.. (2013). Epidemiology, Treatment Outcomes and Costs of Treating Hepatitis C in Routine Care – Results from a Large Multicenter Trial. Value in Health. 16(7). A341–A342. 2 indexed citations
11.
Mauss, Stefan, D. Hueppe, & U. Alshüth. (2013). Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir. Hepatology. 59(1). 46–48. 59 indexed citations
12.
13.
Mauss, Stefan, Christoph Eisenbach, R Heyne, et al.. (2013). 723 Substantial Renal Impairment Is Not Infrequent in HCV Patients Under Triple Therapy With Telaprevir or Boceprevir. Gastroenterology. 144(5). S–960. 1 indexed citations
14.
Boeker, Klaus, Christoph Eisenbach, Bernd Moeller, et al.. (2013). 871 REAL-WORLD EFFICACY AND SAFETY OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON alfa-2a AND RIBAVIRIN: INTERIM ANALYSIS FROM THE GERMAN NON-INTERVENTIONAL PAN STUDY. Journal of Hepatology. 58. S357–S358. 1 indexed citations
15.
Mauss, Stefan, F. Berger, Natalie Filmann, et al.. (2011). Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. Journal of Hepatology. 55(6). 1235–1240. 75 indexed citations
16.
17.
Hueppe, D., C John, R Heyne, et al.. (2010). Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. Journal of Viral Hepatitis. 18(4). e81–90. 19 indexed citations
18.
Witthoeft, T., D. Hueppe, C John, et al.. (2010). Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study. Journal of Viral Hepatitis. 17(7). 459–68. 23 indexed citations
19.
Marotta, Paul, D. Hueppe, E Zehnter, Paul Y. Kwo, & Ira M. Jacobson. (2009). Efficacy of Chronic Hepatitis C Therapy in Community-Based Trials. Clinical Gastroenterology and Hepatology. 7(10). 1028–1036. 13 indexed citations
20.
Zeuzem, Stefan, Thomas Berg, Bernd Moeller, et al.. (2008). Expert opinion on the treatment of patients with chronic hepatitis C. Journal of Viral Hepatitis. 16(2). 75–90. 164 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dessislava I. Dimitrova Breakdown of academic impact, for papers by Natarajan Ravendhran Breakdown of academic impact, for papers by Fernando E. Membreno Breakdown of academic impact, for papers by Ewa Janczewska Breakdown of academic impact, for papers by S. Pol Breakdown of academic impact, for papers by Takeaki Satoh Breakdown of academic impact, for papers by Wulf O. Boecher Breakdown of academic impact, for papers by U. Alshüth Breakdown of academic impact, for papers by Joann Harvey Breakdown of academic impact, for papers by Bart Fevery
Rankless by CCL
2026